A5035201419- Cardiac pacing and defibrillation studies
- Cardiac Arrhythmias and Treatments
- Cardiac electrophysiology and arrhythmias
- Atrial Fibrillation Management and Outcomes
- Cardiomyopathy and Myosin Studies
- Heart Failure Treatment and Management
- Cardiac Health and Mental Health
- Cardiovascular Function and Risk Factors
- Cardiac Structural Anomalies and Repair
- Congenital Heart Disease Studies
- Neurological disorders and treatments
- Cardiovascular Syncope and Autonomic Disorders
- Cardiovascular Effects of Exercise
- Cardiac Valve Diseases and Treatments
- ECG Monitoring and Analysis
- Central Venous Catheters and Hemodialysis
- Viral Infections and Immunology Research
- Stuttering Research and Treatment
- Shoulder Injury and Treatment
- Heart Rate Variability and Autonomic Control
- Vascular anomalies and interventions
- Infective Endocarditis Diagnosis and Management
- Cardiac Imaging and Diagnostics
- Acute Myocardial Infarction Research
- Neuroscience and Neural Engineering
Erasmus MC
2015-2024
Erasmus University Rotterdam
2014-2023
Rotterdam University of Applied Sciences
2012-2018
Auckland City Hospital
2015
Humanitas Gavazzeni
2015
St. Antonius Ziekenhuis
2015
IRCCS Humanitas Research Hospital
2015
Christchurch Hospital
2015
KU Leuven
2015
Ghent University Hospital
2015
Implantable cardioverter-defibrillators (ICDs) prevent sudden death from cardiac causes in selected patients but require the use of transvenous lead systems. To eliminate need for venous access, we designed and tested an entirely subcutaneous ICD system.First, conducted two short-term clinical trials to identify a suitable device configuration assess energy requirements. We evaluated four configurations 78 who were candidates implantation subsequently best 49 additional determine...
The entirely subcutaneous implantable cardioverter-defibrillator (S-ICD) is the first defibrillator that avoids placing electrodes in or around heart. Two large prospective studies (IDE [S-ICD System IDE Clinical Investigation] and EFFORTLESS [Boston Scientific Post Market S-ICD Registry]) have reported 6-month to 1-year data on S-ICD. objective of this study was evaluate safety efficacy a diverse population. Data from were pooled. Shocks independently adjudicated, complications measured...
The totally subcutaneous implantable-defibrillator (S-ICD) is a new alternative to the conventional transvenous ICD system minimize intravascular lead complications. There are limited data describing long-term performance of S-ICD. This paper presents first large international patient population collected as part EFFORTLESS S-ICD Registry. Registry non-randomized, standard care, multicentre designed collect long-term, system-related, clinical, and reported outcome from implanted patients...
The subcutaneous implantable cardioverter-defibrillator (S-ICD) was developed to defibrillate ventricular arrhythmias, avoiding drawbacks of transvenous leads. global EFFORTLESS S-ICD (Evaluation oF FactORs ImpacTing CLinical Outcome and Cost EffectiveneSS the S-ICD) registry is collecting outcomes in 985 patients during a 5-year follow-up. primary goal determine safety by evaluating complications inappropriate shock rate. This first report on full patient cohort study endpoints with...
Arrhythmia Detection with S‐ICD Versus Transvenous ICDs. Background: The development of a totally subcutaneous implantable defibrillator (S‐ICD) system requires new approach for arrhythmia detection. To evaluate discrimination one such system, the Subcutaneous versus Recognition Testing (START) study was designed as prospective, multicenter trial comparing simulated sensing performances single‐ (SC‐TV) and dual‐chamber transvenous (DC‐TV) cardioverter‐defibrillator (ICD) systems. Methods: At...
The impact of alcohol septal ablation (ASA)-induced scar is not known. This study sought to examine the long-term outcome ASA among patients with obstructive hypertrophic cardiomyopathy.Ninety-one consecutive (aged 54+/-15 years) cardiomyopathy underwent ASA. Primary end point was a composite cardiac death and aborted sudden including appropriate cardioverter-defibrillator discharges for fast ventricular tachycardia/ventricular fibrillation. Secondary points were noncardiac other nonfatal...
Objective: We investigated the prevalence of anxiety and depressive symptoms in patients with an implantable cardioverter defibrillator (ICD) their partners, role personality factors social support as determinants distress. Methods: Of all surviving (n = 221) having had ICD implanted between October 1998 January 2003, 182 144 partners completed Hospital Anxiety Depression Scale, Type D Personality Perceived Social Support Scale. defines those who tend to experience increased negative...
BackgroundMost inappropriate shocks from the subcutaneous implantable cardioverter-defibrillator (S-ICD) are caused by cardiac oversensing. A novel sensing methodology, SMART Pass (SP; Boston Scientific Corporation, Natick, MA), aims to reduce oversensing.ObjectiveThe purpose of this study was evaluate effect SP on in ambulatory patients with S-ICD.MethodsPatients implanted 2015–2016 and enrolled a remote patient monitoring system were included followed for 1 year. Shocks adjudicated 3...
Background— The recently released 2014 European Society of Cardiology guidelines hypertrophic cardiomyopathy (HCM) use a new clinical risk prediction model for sudden cardiac death (SCD), based on the HCM Risk-SCD study. Our study is first external and independent validation this model. Methods Results— population consisted consecutive cohort 706 patients with without prior SCD event, from 2 tertiary referral centers. primary end point was composite appropriate implantable...
AimsThe subcutaneous implantable cardioverter defibrillator (S-ICD) was introduced to overcome complications related transvenous leads. Adoption of the S-ICD requires implanters learn a new implantation technique. The aim this study assess learning curve for with respect implant-related complications, procedure time, and inappropriate shocks (IASs).
Abstract Aims To report 5-year outcomes of EFFORTLESS registry patients with early generation subcutaneous implantable cardioverter-defibrillator (S-ICD) devices. Methods and results Kaplan–Meier, trend multivariable analyses were performed for mortality late (years 2–5) complications, appropriate shock (AS) inappropriate (IAS) rates. Nine hundred eighty-four 994 enrolled diverse diagnoses (28% female, 48 ± 17 years, body mass index 27 6 kg/m2, ejection fraction 43 18%) underwent S-ICD...
The prognostic significance of atrial fibrillation (AF) in hospitalized patients with heart failure (HF) remains poorly understood. To evaluate what way AF and its different modes presentation affect the in-hospital mortality admitted HF. EuroHeart Failure Survey was conducted to ascertain how HF are managed Europe. survey enrolled over a 6-week period 115 hospitals from 24 countries. For this analysis, were categorized into three groups according type AF, previous (patients known have had...
Implantable cardioverter-defibrillators (ICDs) reduce mortality in both primary and secondary prevention, but are associated with substantial short- long-term morbidity. A totally subcutaneous ICD (S-ICD) system has been developed. We report the initial clinical experience of first 31 patients implanted at our hospital.All had an indication according to ACC/AHA/ESC guidelines. The 11 were part reported CE trial. implantation was performed without fluoroscopy. device subcutaneously anterior...
The subcutaneous implantable cardioverter-defibrillator (S-ICD) provides an alternative to the transvenous (TV-ICD). Patients undergoing TV-ICD explantation may be eligible for reimplantation with S-ICD; however, information on safety outcomes in this complex population is limited.This analysis was designed provide outcome and data from S-ICD patients who received their device after explantation.Patients IDE Study EFFORTLESS Registry a prior explantation, as well those no (ICD), were...